Abstract
Chronic infection with the hepatitis C virus (HCV) is a common cause of chronic liver disease, cirrhosis, and liver cancer. Like most viruses, HCV depends of a number of factors encoded by its host cell to execute its replication cycle and create. Expression cloning is one of several possible approaches that have been employed to identify novel host factors essential for the HCV replication cycle. It involves generation of a cDNA library from a cell type with a desired trait (such as ability to bind E2 or being susceptible to HCV infection), expression of that library in a different cell type missing the trait of interest, and selection for cell clones that have acquired that trait through expression of a specific cDNA. This chapter describes an expression cloning approach similar to the one that was used to identify the tight junction component claudin-1 as an essential HCV cell entry factor.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Scarselli E, Ansuini H, Cerino R, Roccasecca RM, Acali S, Filocamo G et al (2002) The human scavenger receptor class B type I is a novel candidate receptor for the hepatitis C virus. EMBO J 21:5017–5025
Watashi K, Hijikata M, Hosaka M, Yamaji M, Shimotohno K (2003) Cyclosporin a suppresses replication of hepatitis C virus genome in cultured hepatocytes. Hepatology 38:1282–1288
Nakagawa M, Sakamoto N, Enomoto N, Tanabe Y, Kanazawa N, Koyama T et al (2004) Specific inhibition of hepatitis C virus replication by cyclosporin A. Biochem Biophys Res Commun 313:42–47
Andre P, Komurian-Pradel F, Deforges S, Perret M, Berland JL, Sodoyer M et al (2002) Characterization of low- and very-low-density hepatitis C virus RNA-containing particles. J Virol 76:6919–6928
Wozniak MA, Itzhaki RF, Faragher EB, James MW, Ryder SD, Irving WL et al (2002) Apolipoprotein E-epsilon 4 protects against severe liver disease caused by hepatitis C virus. Hepatology 36:456–463
Toniutto P, Fabris C, Fumo E, Apollonio L, Caldato M, Mariuzzi L et al (2004) Carriage of the apolipoprotein E-epsilon4 allele and histologic outcome of recurrent hepatitis C after antiviral treatment. Am J Clin Pathol 122:428–433
Price DA, Bassendine MF, Norris SM, Golding C, Toms GL, Schmid ML et al (2006) Apolipoprotein epsilon3 allele is associated with persistent hepatitis C virus infection. Gut 55:715–718
Chang KS, Jiang J, Cai Z, Luo G (2007) Human apolipoprotein e is required for infectivity and production of hepatitis C virus in cell culture. J Virol 81:13783–13793
Long G, Hiet MS, Windisch MP, Lee JY, Lohmann V, Bartenschlager R (2011) Mouse hepatic cells support assembly of infectious hepatitis C virus particles. Gastroenterology 141:1057–1066
Pileri P, Uematsu Y, Campagnoli S, Galli G, Falugi F, Petracca R et al (1998) Binding of hepatitis C virus to CD81. Science 282:938–941
Evans MJ, von Hahn T, Tscherne DM, Syder AJ, Panis M, Wolk B et al (2007) Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry. Nature 446:801–805
Ploss A, Evans MJ, Gaysinskaya VA, Panis M, You H, de Jong YP et al (2009) Human occludin is a hepatitis C virus entry factor required for infection of mouse cells. Nature 457:882–886
Derdeyn CA, Decker JM, Sfakianos JN, Wu X, O'Brien WA, Ratner L et al (2000) Sensitivity of human immunodeficiency virus type 1 to the fusion inhibitor T-20 is modulated by coreceptor specificity defined by the V3 loop of gp120. J Virol 74:8358–8367
Demaison C, Parsley K, Brouns G, Scherr M, Battmer K, Kinnon C et al (2002) High-level transduction and gene expression in hematopoietic repopulating cells using a human immunodeficiency [correction of immunodeficiency] virus type 1-based lentiviral vector containing an internal spleen focus forming virus promoter. Hum Gene Ther 13:803–813
Cowan S, Hatziioannou T, Cunningham T, Muesing MA, Gottlinger HG, Bieniasz PD (2002) Cellular inhibitors with Fv1-like activity restrict human and simian immunodeficiency virus tropism. Proc Natl Acad Sci U S A 99:11914–11919
Zennou V, Bieniasz PD (2006) Comparative analysis of the antiretroviral activity of APOBEC3G and APOBEC3F from primates. Virology 349:31–40
Reed LJ, Muench H (1938) A simple method of estimating fifty per cent endpoints. Am J Hyg 27:493–497
Acknowledgments
The authors would like to acknowledge Theodora Hatziioannou and Paul Bieniasz of Aaron Diamond AIDS Research Center (NY, USA) who conceived, designed, generated, and provided the V1 vector enabling a CPR-based cloning strategy. The authors would also like to acknowledge the contribution of Charles Rice (The Rockefeller University, NY, USA) and Matthew Evans (Mount Sinai School of Medicine, NY, USA) who made very major contributions to devising the HCV-customized strategy described here.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Science+Business Media, LLC, part of Springer Nature
About this protocol
Cite this protocol
Ciesek, S., von Hahn, T. (2019). Expression Cloning of Host Factors Required for the HCV Replication Cycle. In: Law, M. (eds) Hepatitis C Virus Protocols . Methods in Molecular Biology, vol 1911. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-8976-8_11
Download citation
DOI: https://doi.org/10.1007/978-1-4939-8976-8_11
Published:
Publisher Name: Humana Press, New York, NY
Print ISBN: 978-1-4939-8975-1
Online ISBN: 978-1-4939-8976-8
eBook Packages: Springer Protocols